The use of ANT2 shRNA in combination with TRAIL up-regulates DR4/DR5 expression and down-regulates DcR2 expression in vitro and in vivo, inducing apoptosis in a TRAIL-resistant human breast cancer cell line and enhancing survival in a tumor-bearing mouse model. Here, TNFRSF10D is linked to breast carcinoma.